Inibidores do SGLT-2

Funding Information: José Silva-Cardoso has received speaker and consultant fees, advisory board participation fees, or investigational grants from Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servi...

ver descrição completa

Detalhes bibliográficos
Autor principal: Silva-Cardoso, José (author)
Outros Autores: Andrade, Aurora (author), Brito, Dulce (author), Ferreira, Jorge (author), Fonseca, Cândida (author), Peres, Marisa (author), Franco, Fátima (author), Moura, Brenda (author)
Formato: review
Idioma:por
Publicado em: 2021
Assuntos:
Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
Texto completo:http://hdl.handle.net/10362/120537
País:Portugal
Oai:oai:run.unl.pt:10362/120537

Texto Completo

http://hdl.handle.net/10362/120537

Registros relacionados